Dr Wilson was Senior Vice President for Medical and Regulatory Affairs for Boehringer Ingelheim Pharmaceuticals (USA) for ten years where he oversaw a team of 400, including a number of medical staff, and was responsible for over 50 parallel drug developments. Subsequently, head of Boehringer's worldwide medical research group overseeing all research programmes and working on upward of 100 drugs, he later relocated to Ingelheim (Germany) as head of Medicine and Regulatory Affairs worldwide. He is also Executive Chairman of ASX-listed biotech Phylogica (a drug discovery company) and is a director of Sea Dragon (a New Zealand company producing omega-3 oils by molecular distillation of fish oil).
drug developement